OBJECTIVE: To assess the effects of low-dose acetazolamide treatment on volumetric MRI markers and clinical outcome in idiopathic normal-pressure hydrocephalus (iNPH). METHODS: We analyzed MRI and gait measures from 8 patients with iNPH with serial MRIs from an institutional review board-approved imaging protocol who had been treated off-label with low-dose acetazolamide (125-375 mg/day). MRI studies included fluid-attenuated inversion recovery and 3D T1-weighted high-resolution imaging. Automated analyses were employed to quantify each patient's ventricular, global white matter hyperintensities (WMH), and periventricular WMH (PVH) volumes prior to and throughout treatment. Clinical outcome was based on gait changes assessed quantitatively using the Boon scale. RESULTS: Five of 8 patients responded positively to treatment, with median gait improvement of 4 points on the Boon scale. A significant decrease in PVH volume (-6.1 ± 1.9 mL, p = 0.002) was seen in these patients following treatment. One patient's gait was unchanged and 2 patients demonstrated worsened gait and were referred for shunt surgery. No reduction in PVH volume was detected in the latter 2 patients. Nonperiventricular WMH and lateral ventricle volumes remained largely unchanged in all patients. CONCLUSIONS: These preliminary findings provide new evidence that low-dose acetazolamide can reduce PVH and may improve gait in iNPH. PVH volume, reflecting transependymal CSF, is shown to be a potential MRI indicator of pharmacologic intervention effectiveness. Further studies of pharmacologic treatment of iNPH are needed and may be enhanced by incorporating quantitative MRI outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that low-dose acetazolamide reverses PVH volume and, in some cases, improves gait in iNPH.
OBJECTIVE: To assess the effects of low-dose acetazolamide treatment on volumetric MRI markers and clinical outcome in idiopathic normal-pressure hydrocephalus (iNPH). METHODS: We analyzed MRI and gait measures from 8 patients with iNPH with serial MRIs from an institutional review board-approved imaging protocol who had been treated off-label with low-dose acetazolamide (125-375 mg/day). MRI studies included fluid-attenuated inversion recovery and 3D T1-weighted high-resolution imaging. Automated analyses were employed to quantify each patient's ventricular, global white matter hyperintensities (WMH), and periventricular WMH (PVH) volumes prior to and throughout treatment. Clinical outcome was based on gait changes assessed quantitatively using the Boon scale. RESULTS: Five of 8 patients responded positively to treatment, with median gait improvement of 4 points on the Boon scale. A significant decrease in PVH volume (-6.1 ± 1.9 mL, p = 0.002) was seen in these patients following treatment. One patient's gait was unchanged and 2 patients demonstrated worsened gait and were referred for shunt surgery. No reduction in PVH volume was detected in the latter 2 patients. Nonperiventricular WMH and lateral ventricle volumes remained largely unchanged in all patients. CONCLUSIONS: These preliminary findings provide new evidence that low-dose acetazolamide can reduce PVH and may improve gait in iNPH. PVH volume, reflecting transependymal CSF, is shown to be a potential MRI indicator of pharmacologic intervention effectiveness. Further studies of pharmacologic treatment of iNPH are needed and may be enhanced by incorporating quantitative MRI outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that low-dose acetazolamide reverses PVH volume and, in some cases, improves gait in iNPH.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: A J Boon; J T Tans; E J Delwel; S M Egeler-Peerdeman; P W Hanlo; J A Wurzer; J Hermans Journal: Eur J Neurol Date: 1997-01 Impact factor: 6.089
Authors: S Pujari; S Kharkar; P Metellus; J Shuck; M A Williams; D Rigamonti Journal: J Neurol Neurosurg Psychiatry Date: 2008-03-20 Impact factor: 10.154
Authors: Joshua Z Willey; Yeseon P Moon; Mandip S Dhamoon; Erin R Kulick; Ahmet Bagci; Noam Alperin; Ying Kuen Cheung; Clinton B Wright; Ralph L Sacco; Mitchell S V Elkind Journal: Neuroepidemiology Date: 2018-06-28 Impact factor: 3.282
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Ahmet Bagci; Noam Alperin; Ralph L Sacco; Mitchell S V Elkind; Clinton B Wright Journal: J Am Geriatr Soc Date: 2017-11-20 Impact factor: 5.562
Authors: Angela C C Jochems; Susana Muñoz Maniega; Maria Del C Valdés Hernández; Gayle Barclay; Devasuda Anblagan; Lucia Ballerini; Rozanna Meijboom; Stewart Wiseman; Adele M Taylor; Janie Corley; Francesca M Chappell; Ellen V Backhouse; Michael S Stringer; David Alexander Dickie; Mark E Bastin; Ian J Deary; Simon R Cox; Joanna M Wardlaw Journal: Neuroimage Clin Date: 2022-04-26 Impact factor: 4.891
Authors: Erik N T P Bakker; Brian J Bacskai; Michal Arbel-Ornath; Roxana Aldea; Beatrice Bedussi; Alan W J Morris; Roy O Weller; Roxana O Carare Journal: Cell Mol Neurobiol Date: 2016-03-18 Impact factor: 5.046
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Ahmet Bagci; Noam Alperin; Ralph L Sacco; Mitchell S V Elkind; Clinton B Wright Journal: Front Aging Neurosci Date: 2017-09-20 Impact factor: 5.750